

**Subject:** SV: SV: SV: Country Drug Reports (CDRs) State of progress

**From:** Sandøy, Thomas Anton <Thomas.Sandoy@fhi.no>

**Date:** 02/06/2017 14:44

**To:** Ilze Jekabsone <Ilze.Jekabsone@emcdda.europa.eu>, "Jane.Mounteney@emcdda.europa.eu" <Jane.Mounteney@emcdda.europa.eu>

**CC:** Bilgrei, Ola Røed <ola.roed.bilgrei@fhi.no>

Dear Ilze,

Thank you for amending the DRD section. As for the at glance figure, your reasoning makes sense to me. By including 'at the end of 2016', I believe the emphasized quote would be correct. Thanks for the swift assistance!

See you around Lisbon,  
Thomas Anton

---

**Fra:** Ilze Jekabsone [mailto:Ilze.Jekabsone@emcdda.europa.eu]

**Sendt:** torsdag 1. juni 2017 19:56

**Til:** Sandøy, Thomas Anton <Thomas.Sandoy@fhi.no>; Jane.Mounteney@emcdda.europa.eu

**Kopi:** Bilgrei, Ola Røed <ola.roed.bilgrei@fhi.no>

**Emne:** Re: SV: SV: Country Drug Reports (CDRs) State of progress

Dear Thomas,

We will ask the amendment of DRD section, as you requested. With regards to other two requests:

- we discussed the note to the At the glance, but we decided to avoid it as there is already a note referring to other sources which provide the methodological guidance.
- for the quote, we have agreed to take out number of cities, but this would require to rephrase the sentence. Would it be correct to finish the quote saying 'at the end of 2016' and it would read Take-home naloxon projects were running in seven cities and injection rooms were operational in two cities at the end of 2016'.

Please let me know!

Enjoy the Lisbon!

Ilze

On 31/05/2017 16:50, Sandøy, Thomas Anton wrote:

Hi once again,

Sorry for adding another comment at this point, but after discussing the matter of comparing DRD-rates with my Scandinavian colleagues, I realize that a cautionary note would improve the Norwegian CDR as well. Following this, I wonder if the text on page 9 could be changed into (mirroring Denmark):

'The latest European average of drug-induced mortality rate among adults (aged 15-64 years) was 20.3 deaths per million. In Norway, this rate was 75.6 deaths per million in 2014 (Figure 10). Comparison between countries should be undertaken with caution. Reasons include systematic under-reporting in some countries, different reporting systems and case definition and registration processes.'

Again, we are really happy about the product J

**Best regards**

**Thomas Anton Sandøy**

Head of focal point (EMCDDA), phd candidate  
Department of Substance Use | Norwegian Institute of Public Health  
Postal address: PO Box 4404, Nydalen, N-0403 Oslo, Norway  
Visiting address: Sandakerveien 24C, 0473 Oslo  
Tel: (+47) 40627424  
[www.fhi.no](http://www.fhi.no)

 <http://www.fhi.no/dokumenter/8bf8>

---

**Fra:** Ilze Jekabsone [<mailto:Ilze.Jekabsone@emcdda.europa.eu>]

**Sendt:** onsdag 31. mai 2017 11.52

**Til:** Sandøy, Thomas Anton <[Thomas.Sandoy@fhi.no](mailto:Thomas.Sandoy@fhi.no)>; [Jane.Mounteney@emcdda.europa.eu](mailto:Jane.Mounteney@emcdda.europa.eu)

**Kopi:** Bilgrei, Ola Røed <[ola.roed.bilgrei@fhi.no](mailto:ola.roed.bilgrei@fhi.no)>

**Emne:** Re: SV: Country Drug Reports (CDRs) State of progress

Dear Thomas,

thank you for the comments, we will review and see if it is possible to adopt them tomorrow with the CDR group.

Best regards,  
Ilze

On 31/05/2017 11:27, Sandøy, Thomas Anton wrote:

Dear Ilze,  
Dear Jane,

First of all, congratulations on producing an excellent product in such a short time. We are truly grateful (and impressed). We are very much looking forward to seeing how the CDR will be utilized at a national level and believe it will raise our profile.

Also, thank you for taking our feedback into consideration. We went through the latest version yesterday and were quite happy about it J

If we were to comment on something:

- The estimate for syringes distributed in the 'at glance' figure on page 1 is a low estimate based only on reporting from 17 municipalities. This is expressed in the text on p. 11, but given the user friendly nature of the front page infographics, it could be good to include a footnote here
- The emphasized text on p. 12 is already a bit outdated. Things are happening fast in the naloxone area, and take-home naloxone projects are now running in eleven cities. Maybe the number could easily be changed? Then again, a time lag is to be expected in such a publication.

The main message coming from us in Norway is thank you. If the two points are not attended to, we remain very satisfied.

**All the best**

**Thomas Anton Sandøy**

Head of focal point (EMCDDA), phd candidate  
Department of Substance Use | Norwegian Institute of Public Health  
Postal address: PO Box 4404, Nydalen, N-0403 Oslo, Norway  
Visiting address: Sandakerveien 24C, 0473 Oslo  
Tel: (+47) 40627424  
[www.fhi.no](http://www.fhi.no)

 <http://www.fhi.no/dokumenter/8bf8>

---

**Fra:** Ilze Jekabsone [<mailto:Ilze.Jekabsone@emcdda.europa.eu>]

**Sendt:** mandag 29. mai 2017 16.37

**Til:** Austrian Head of Focal Point <Marion.Weigl@goeg.at>; Belgian Focal Point <BMCDDA@wiv-isp.be>; Belgian Head of Focal Point <Lies.Gremeaux@wiv-isp.be>; Bulgarian Head of Focal Point <mvassilev@mail.bg>; Croatian Head of Focal Point <lidija.vugrinec@uredzadroge.hr>; Cyprus Head of Focal Point <ioanna@ask.org.cy>; Czech Head of Focal Point <mravcik.viktor@vlada.cz>; Danish Head of Focal Point <kag@sst.dk>; Dutch Head of Focal Point <mlaar@trimbos.nl>; Estonian Head of NFP a.i. <katri.abel-ollo@tai.ee>; European Commission Focal Point <paola.mazzarini@ec.europa.eu>; Finnish Co-Head of Focal Point <sanna.ronka@thl.fi>; French Focal Point <andel@ofdt.fr>; French Head of Focal Point <Francois.Beck@ofdt.fr>; German Focal Point <freitag@ift.de>; German Head of Focal Point <Pfeiffer-Gerschel@ift.de>; Greek Head of Focal Point <mterzidou@ektepn.gr>; Hungarian Head of NFP <horvath.gergely@nefi.hu>; Irish Head of Focal Point <bgalvin@hrb.ie>; Italian Head of Focal Point <e.simeoni@governo.it>; Latvian Focal Point <linda.sile@spkc.gov.lv>; Latvian Head of Focal Point <ieva.pugule@spkc.gov.lv>; Lithuanian Head of Focal Point <Lina.Jurgelaitiene@NTAKD.lt>; Luxembourg Head of Focal Point <alain.origer@ms.etat.lu>; Maltese Focal Point <nfp.msoc@gov.mt>; Maltese Head of Focal Point <carlo.olivari-demanuele@gov.mt>; Sandøy, Thomas Anton <Thomas.Sandoy@fhi.no>; Bilgrei, Ola Røed <ola.roed.bilgrei@fhi.no>; Polish Head of Focal Point <Artur.Malczewski@kbpn.gov.pl>; Portuguese Head of Focal Point <Joao.Goulao@sicad.min-saude.pt>; Portuguese National Focal Point <Oscar.Duarte@sicad.min-saude.pt>; Portuguese National Focal Point <Sofia.Santos@sicad.min-saude.pt>; Romanian Head of Focal Point <ruxanda.iliescu@ana.gov.ro>; Slovakian Head of Focal Point <imrich.steliar@health.gov.sk>; Slovenian Head of Focal Point <Milan.krek@nijz.si>; Slovenian NFP <droge@nijz.si>; Spanish Head of Focal Point <relinstipnd@msssi.es>; Spanish National Focal Point <rsendino@msssi.es>; Swedish Head of Focal Point <joakim.strandberg@folkhalsomyndigheten.se>; Turkish Head of Focal Point <tr-nfp@egm.gov.tr>; United Kingdom Head of NFP <Craig.Wright@phe.gov.uk>

**Kopi:** Goncalo Felgueiras <Goncalo.Felgueiras@emcdda.europa.eu>; EMCDDA-RTX <EMCDDA-RTX@emcdda.europa.eu>; Rosemary de Sousa <Rosemary.de.Sousa@emcdda.europa.eu>; Jane Mounteney <Jane.Mounteney@emcdda.europa.eu>

**Emne:** Re: Country Drug Reports (CDRs) State of progress

Dear all,

I would like to let you know that the 2017 Country Drug Reports are available for your consultation from the Reitox extranet. You can access access them by the country name: <https://reitox.emcdda.europa.eu/html.cfm/index255957EN.html>

As all other EDR-related materials, they are under embargo till 6 June.

Thank you for your contribution!

Best regards and see you this week in Lisbon,  
Ilze

On 22/05/2017 19:40, Goncalo Felgueiras wrote:

Dear colleagues,

In the last days we have received a few requests from you to release final versions of Country Drug Reports (CDR).

I would like to tell you that the CDR production team is working very

very intensively to finalise the CDR pdf versions by 6 June 2017, to be launched together with the 2017 European Drug Report (in English).

I would like to take this opportunity and thank everyone for their inputs during the consultation and checking process. Following your feedback, the content of the CDRs was further corrected and improved. Moreover, we had run several data validation exercises and also English language proofreading of the documents.

All 30 CDRs are currently in the lay-out phase. We have received this morning the 3<sup>rd</sup> proofs from the publication company and we will work on them this week.

I know that you are all keen to see the final product and I would like to assure that we are doing as much as possible from our side to get the final versions to you.

As soon as the CDR English versions will be finalised we will make them available through the EDR 2017 page on the Reitox extranet. Likewise to the EDR, their distribution will be embargoed until 6 June.

Thank you for your cooperation,

Kind regards,

Gonçalo



**Gonçalo Felgueiras e Sousa**

Head of unit  
Reitox and external partners  
Tel. (351) 211 21 02 31

**European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)**

Praça Europa 1, Cais do Sodré, 1249-289 Lisbon, Portugal •  
[www.emcdda.europa.eu](http://www.emcdda.europa.eu)

---

**EMCDDA, chair of the network of Justice and Home Affairs agencies in 2017**

*Please consider the impact on the environment before printing this email.*

--



**Ilze Jekabsone**

Capacity development officer  
Reitox and external partners unit  
Tel. (351) 211 21 02 27

**European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)**

Praça Europa 1, Cais do Sodré, 1249-289 Lisbon, Portugal • [www.emcdda.europa.eu](http://www.emcdda.europa.eu)

*Please consider the impact on the environment before printing this email.*

--



**Ilze Jekabsone**

Capacity development officer  
Reitox and external partners unit  
Tel. (351) 211 21 02 27

**European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)**

Praça Europa 1, Cais do Sodré, 1249-289 Lisbon, Portugal • [www.emcdda.europa.eu](http://www.emcdda.europa.eu)

*Please consider the impact on the environment before printing this email.*

--



**Ilze Jekabsone**

Capacity development officer  
Reitox and external partners unit  
Tel. (351) 211 21 02 27

**European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)**

Praça Europa 1, Cais do Sodré, 1249-289 Lisbon, Portugal • [www.emcdda.europa.eu](http://www.emcdda.europa.eu)

*Please consider the impact on the environment before printing this email.*